Why the study?
The NLRP3 inflammasome is implicated in metabolic disturbances, but whether its inhibition could ameliorate obesity-associated cardiomyopathy and the underlying mechanisms remained unclear.
Does NLRP3 inflammasome inhibition ameliorate cardiac remodeling and dysfunction in obesity-associated cardiomyopathy?
Population
Male mice fed a high-fat diet and neonatal rat ventricular myocytes
Comparison
NLRP3 inflammasome inhibition or TXNIP modulation vs controls
Design
Preclinical animal and in vitro mechanistic study
Authors
Loading...
Supports NLRP3 inhibition in obesity cardiomyopathy; hypothesis-generating from animal data requiring human trials.
Does NLRP3 inflammasome inhibition ameliorate cardiac remodeling and dysfunction in obesity-associated cardiomyopathy?
Inhibition of the NLRP3 inflammasome prevents cardiac remodeling and dysfunction in a murine model of obesity-associated cardiomyopathy.
Liu et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: